Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPG-818 First-in-Human Study in Healthy Participants
NCT03949426Phase 1Completed
- Sponsor
- Kangpu Biopharmaceuticals
- Start
- May 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing KPG-818 with Placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events and Maximum Tolerated Dose. Started May 2019; status: completed.
02
Drugs
epaldeudomide
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03949426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03949426.